NASDAQ · SNDX
Healthcare · Biotechnology
$13.65
Down-$0.50 (-3.53%)
Updated Oct 31, 2026, 1:36 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SNDX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SNDX closed at $13.65 after 21 trading sessions, down 22.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $14.06 | $14.35 | $13.61 | $13.65 | 2.54M |
| Oct 29, 2026 | $14.36 | $14.655 | $13.98 | $14.15 | 4.88M |
| Oct 28, 2026 | $13.52 | $14.34 | $13.49 | $14.32 | 2.75M |
| Oct 27, 2026 | $13.25 | $13.88 | $13.05 | $13.69 | 2.7M |
| Oct 26, 2026 | $13.58 | $13.70 | $13.12 | $13.22 | 1.99M |
| Oct 23, 2026 | $13.60 | $13.608 | $13.20 | $13.40 | 4.25M |
| Oct 22, 2026 | $13.06 | $13.58 | $13.05 | $13.57 | 2.36M |
| Oct 21, 2026 | $13.32 | $13.5871 | $13.10 | $13.15 | 2.59M |
| Oct 20, 2026 | $13.20 | $13.59 | $12.97 | $13.25 | 3.91M |
| Oct 19, 2026 | $12.95 | $13.18 | $12.795 | $13.09 | 2.19M |
| Oct 16, 2026 | $13.65 | $13.655 | $12.815 | $12.90 | 2.84M |
| Oct 15, 2026 | $13.58 | $14.05 | $13.43 | $13.65 | 2.63M |
| Oct 14, 2026 | $13.92 | $14.005 | $13.39 | $13.53 | 3.04M |
| Oct 13, 2026 | $14.61 | $14.74 | $13.49 | $13.95 | 6.81M |
| Oct 12, 2026 | $16.88 | $16.95 | $16.37 | $16.55 | 2.03M |
| Oct 9, 2026 | $16.91 | $17.42 | $16.78 | $16.99 | 1.46M |
| Oct 8, 2026 | $16.90 | $17.285 | $16.39 | $16.90 | 2.14M |
| Oct 7, 2026 | $17.17 | $17.695 | $17.03 | $17.03 | 1.59M |
| Oct 6, 2026 | $17.99 | $18.19 | $16.85 | $17.37 | 1.14M |
| Oct 5, 2026 | $17.58 | $17.98 | $17.57 | $17.83 | 1.46M |
| Oct 2, 2026 | $18.46 | $18.46 | $17.52 | $17.60 | 2.56M |
The latest Smart Investors Daily articles mentioning SNDX.
Company
Market Activity
Research & News
SNDX research
Company profile and research snapshot.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 21, 2026 | UBS | Buy | — |
| Aug 11, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 26, 2026
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 26, 2026
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 2, 2026. The live audio webcast and accompanying
Yahoo · Oct 15, 2026
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company’s first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category. TIME’s annual list of the Best Inventions features 300 extraordinary inventions changing lives. To compile this year's list, TIME solicit
Yahoo · Oct 14, 2026
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNDX.
